Saturday, October 1, 2022

Winning Again! FEELM Max Awarded the Golden Leaf Award for "Most Promising Innovation"

WASHINGTON - Thursday, 29. September 2022

(BUSINESS WIRE)--FEELM, the flagship atomization technology platform belonging to SMOORE - the world’s largest vape manufacturer, has won the Golden Leaf Award for "Most Promising Innovation" at the 2022 Global Tobacco and Nicotine Forum (GTNF) in Washington, DC.

“Using FEELM’s updated ceramic coil technology, the FEELM Max offers improved flavor consistency, more puffs and reduced harshness through smaller aerosol particles. Most importantly, the FEELM Max offers greater potential for harm reduction,” the organizer of GTNF announced at the award ceremony.

Four years ago, FEELM tech won the Golden Leaf Award. And four years later, FEELM Max won the Golden Leaf Award again, it is also FEELM Max's second global award this year after winning the Red Dot Award.

The Golden Leaf Award is one of the most prestigious awards in the sector and is designed to recognize companies and brands that have made outstanding contributions to the global tobacco and nicotine industry. The "Most Promising Innovation" award was open to companies that are launching new technologies and products, and was judged based on design innovation and projected future production efficiencies.

Speaking at the award ceremony, Chief Scientist of SMOORE American Research Institute, Dr. Shi, said:

"We have a long and extensive portfolio of breakthrough technologies to enhance the product experience, and we are delighted that FEELM Max has won, and our efforts have been recognized by global industry experts."

Today's new award represents another milestone in the continuing evolution of FEELM technology. With new materials, microstructures and processes, the FEELM Max technology sets a new bar in even more harm reduction and product performance improvement. It embodies the mission of the parent company Smoore International: innovation for better well-being, which ties well with the theme of this conference "Science, technology and innovation driving transformation."

According to the evaluation of industry experts, the technology within FEELM Max has the potential to bring the quality associated with reusable vaping products into the disposable market. As the world's first disposable atomization solution with a ceramic core, FEELM Max relies on its underlying technological innovation to surpass the traditional cotton core solution. It provides disposable products with "better taste, more puff, and higher consistency."

FEELM's single-use solutions are now sold in countries around the world, including in major economies like the United States, United Kingdom. SMOORE's interim financial report for 2022 showed that the revenue of disposable products in the first half of the year reached 319 million yuan, up 234.5 percent from the same period last year.

In addition to redefining products with technological innovation and creating a better vaping experience, FEELM Max also aims to have a lower carbon footprint than comparable products by introducing a series of green and sustainable technical solutions covering packaging, materials, and production.

The 2020 and 2021 GTNF awards had been postponed to 2022 due to the COVID-19 pandemic, which meant the competition was more intense than ever. The winners represented the innovations in the industry over the past three years, making FEELM even more proud to have won this award.


For more information or journalist queries, please contact Tommy Gilchrist on 0044 7388 110 679 or via

About FEELM:

As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.


SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.

According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.


View source version on



Tommy Gilchrist

0044 7388 110 679

Friday, September 30, 2022

Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine

 EDMONTON, Alberta & OUAGADOUGOU, Burkina Faso

This phase 2 trial evaluates the safety, tolerability, and immunogenicity of Covigenix VAX-001-1b in healthy adults 18 years and older

A total of 268 participants have been enrolled in the study at two sites in Burkina Faso, completing the single and two-dose cohorts

(BUSINESS WIRE) -- Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and Centre National de Recherche et de Formation sur le Paludisme (CNRFP), the Burkina Faso site team lead by Dr. Gansane Adama, announced today that enrollment is now complete into the single and two-dose cohorts of the Phase 2 clinical trial of Covigenix VAX-001-1b (Covigenix), its COVID-19 DNA vaccine. A total of 268 participants are enrolled in the study at two sites in Burkina Faso. The phase 2 trial in Burkina Faso is managed by Clinical Pharma Solutions Inc. based in Ontario, Canada.

“We’re thrilled that recruitment for our Phase 2 trial of our COVID-19 DNA vaccine was completed so quickly by Dr. Adama’s team in Burkina Faso. We’d like to extend our deepest gratitude to all the study participants, without whom, this milestone would not be possible,” said John D. Lewis, Ph.D., founder, and CEO of Entos Pharmaceuticals. “The continued progress of our Covigenix vaccine clinical development program brings us closer towards providing a potentially effective and safe fridge-stable, single-dose vaccine against COVID-19 to under-vaccinated regions of the world.”

Formulated using Entos’ Fusogenix PLV delivery platform, Covigenix is a DNA vaccine encoding SARS-CoV-2 Spike protein and two genetic adjuvants engineered to stimulate the adaptive and innate immune systems. By stimulating both arms of the immune system, the vaccine is designed to provide effective and durable protection against COVID-19. Preclinical studies of Covigenix demonstrated potent immunogenicity, conferring protection from infection with SARS-CoV-2 in animal models. Given the high stability of DNA, Covigenix has the key advantage of stability for more than a year at normal refrigerated temperatures, making it more cost-effective to store, transport, and deploy to developing countries compared to approved vaccines.

The ongoing Phase 2 trial was preceded by a first-in-human Phase 1 study conducted in Canada. In Phase 1, Entos’ Fusogenix PLV platform was determined to be safe and well-tolerated for the intracellular delivery of DNA, with the potential to promote positive immunological outcomes in a single vaccine dose. The ongoing Phase 2 randomized, observer-blind clinical trial in Burkina Faso is further evaluating the safety, tolerability, and immunogenicity of Entos’ single-dose and double-dose regimens of the intramuscularly administered Covigenix DNA vaccine candidate in healthy adults 18 or older.

“Despite the availability of mRNA-based vaccines, COVID-19 is still a major problem in Burkina Faso and other countries with vulnerable populations,” said Dr. Gansane Adama, Principal Investigator with CNRFP. “We need vaccines that are safe, effective, and easy to transport, store, and administer. With the study now fully enrolled, we look forward to generating data that can inform the potential utility of this important investigational vaccine.”

For more information about Entos and its COVID-19 vaccine visit

About Entos Pharmaceuticals Inc.

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion. For more information, visit, or follow Entos on Twitter or LinkedIn.


The Centre National de Recherche et de Formation sur le Paludisme (CNRFP) is a research institution from the National Public Health Institute and funded by the Ministry of Health of Burkina Faso since 1983, as a need to foster quality research that will contribute to evidence-based decision making for the policymakers in Burkina Faso. The institution has its main offices in Ouagadougou, the capital city of Burkina Faso. The CNRFP has developed two research stations, located in Banfora (Clinical Research Unit of Banfora) and Sapone (Clinical Trial Centre of Balonghin), well-equipped to undertake clinical trials at any phase, compliant with national and international regulations.

The research platforms from CNRFP made contributions to the development of vaccines candidate (malaria, Ebola, Covid-19) and antimalarial drug development with support and funds from the Ministry of Health and international partners. For more information, visit the website

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Entos' belief as to the mode of action and potential and benefits of Fusogenix proteolipid vehicle platform; the mode of action and potential and benefits of Covigenix VAX-001-1b (Covigenix) as a COVID-19 vaccine; Entos' plans to advance towards a phase 3 study for COVID-19; and other statements related to anticipated developments in Entos' business and technologies. In any forward-looking statement in which Entos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Entos' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of Fusogenix as a nucleic acid delivery vehicle, the efficacy of Covigenix as a COVID-19 vaccine, the success and timely completion of clinical studies and trials, Entos' ability to successfully commercialize Covigenix, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Entos may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition. Investors should consult with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.


View source version on



Entos Pharmaceuticals Corporate Contact:

John Lewis, Ph.D., Founder and CEO

Entos Pharmaceuticals Media Contact:

Perrin Beatty, PhD.



Dr. Gansane Adama, PharmD, Msc, PhD




ABB to Sell Remaining Stake in Hitachi Energy to Hitachi

 (BUSINESS WIRE) -- ABB has reached an agreement to divest to Hitachi, Ltd. (Hitachi) its remaining 19.9 percent equity stake in the Hitachi Energy joint venture that was formed from ABB’s Power Grids business in 2020, with Hitachi holding a stake of 80.1 percent. Hitachi has exercised its call option that was agreed between the parties in December 2018.

The call option’s exercise value is $1.679 billion. The companies have agreed to settle remaining obligations relating to the original transaction, and ABB will continue to provide transition services to Hitachi Energy for them to fully separate from ABB’s systems. ABB does not expect to record any significant gain or loss as a result of the sale. ABB expects net positive cash inflows of approximately $1.425 billion upon closing of the sale. The transaction is subject to regulatory approvals and closing is expected to happen in the fourth quarter 2022.

“We are delighted to have agreed on the final part of the transaction earlier than expected and on favorable terms. This will further strengthen our balance sheet and give us additional flexibility in our capital allocation decisions,” said Timo Ihamuotila, Chief Financial Officer of ABB.

ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 105,000 talented employees in over 100 countries.

Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at

Important notice about forward-looking information

This press release includes forward-looking information and statements which are based on current expectations, estimates and projections about the factors that may affect our future performance. These are generally identifiable by statements containing words such as “expects”, “estimates”, or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release. These include business risks associated with the volatile global economic environment and political conditions, costs associated with compliance activities, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.


View source version on




Affolternstrasse 44

8050 Zurich


Media Relations

+41 43 317 71 11

Investor Relations

+41 43 317 71 11


Mavenir to Deliver Cloud-Based 5G Solutions on Google Cloud

 RICHARDSON, Texas - Friday, 30. September 2022 AETOSWire 

Solution includes containerized and micro-serviced Converged 5G Packet Core, IP Multimedia Subsystem (IMS), Messaging, Orchestration, AI and Telco Analytics, and Open RAN products

(BUSINESS WIRE) -- Mavenir announces integration of cloud-native 5G solutions with public cloud infrastructure on Google Cloud, expanding on Mavenir’s “One Network, Any Cloud All Software” strategy.

Mavenir’s collaboration with Google Cloud will allow Communications Service Providers (CSPs) deploy its 5G products and applications with Google Cloud’s scalable infrastructure, container deployment, management technologies, and big data analytics services. By offloading parts of the standard telecommunication application business to cloud functions, Mavenir’s solution reduces complexity and costs for CSPs without losing insights, performance, and network control.

Mavenir is a Network Software Provider innovating the future of networks with cloud-native software that runs on any cloud. This collaboration demonstrates true cloud-native Open RAN products in production deployment on Google Distributed Cloud. Open RAN technology separates software from hardware, meaning more flexibility for mobile operators and customers. The Open RAN approach will see many companies providing the components that make up a mobile network site, where previously one vendor would have delivered a closed solution. The technology is widely accepted as a disruptor for the telecommunications industry, with Tier 1 operators as some of the early adopters in supporting the development of this vendor ecosystem.

Validation of Mavenir’s Open RAN product in Google Cloud allows CSPs to deploy Mavenir’s 5G Open RAN products with Google Distributed Cloud Edge, global infrastructure and state-of-the-art unified container platform Anthos. The fully containerized Distributed Units (DUs) and Central Units (CUs) software run on Google Distributed Cloud Edge, enabled by Anthos, and Mavenir’s Webscale Telco PaaS to deliver ORAN-compliant RAN networks. Validation testing includes end-to-end UE calls with other simulated 5G network components. The critical DU components are incorporated with Google Distributed Cloud Edge’s new OS and RT kernel.

Mavenir’s cloud-native 5G core (5GC) and IMS solution are also suited for large-scale production deployment on Google Cloud infrastructure. By leveraging Google Cloud’s service-centric networking, advanced computers, and reliable and secure storage, Mavenir’s Network Functions offer performance on par with on-prem deployment while benefiting from offloading the infrastructure services to Google Cloud. Google Cloud’s global reach extends CSPs’ services to new areas where they were previously unavailable. Tier 1 operators are planning Mavenir’s Remote Packet Gateway (RPG) global deployments via Google Cloud’s expansive coverage in 200+ countries and territories.

The collaboration has benefited from deep technical engagement between Mavenir and Google Cloud. As an innovative ISV in 5G products and solutions, Mavenir continues to expand and optimize its offerings of fully end-to-end 5G network systems.

“Working with Google Distributed Cloud Edge enables us to bring innovative 5G products to a broader customer base at faster pace with unique capabilities to realize true 5G potential leveraging strength within the Mavenir portfolio,” said Bejoy Pankajakshan, Mavenir’s Chief Technology & Strategy Officer. “Mavenir’s 5G solutions are proven to support full public cloud as well as hybrid cloud deployments.”

“We’re delighted to collaborate with Mavenir to offer Open RAN solutions for 5G networks,” said Amol Phadke, GM: Global Telecom Industry, Google Cloud. “Combining Mavenir’s expertise in Open RAN, 5G core, and IMS with Google Distributed Cloud Edge and global infrastructure, we look forward to providing cloud-native solutions that improve agility, scale, slicing, and resiliency for our CSP customers.”

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.


View source version on



Mavenir PR Contacts:

Maryvonne Tubb (US)

Emmanuela Spiteri (EMEA)

Italian mattress brand Mollyflex opens first branch in the UAE

 Mollyflex, a brand that has over 40 years of experience in the art and science of promoting restful sleep through innovative products, has recently opened its first branch in Dubai. Its 5,500 sq. ft showroom is located in Al Safa Dubai, in Sunrise Building at Sheikh Zayed Road, and displays a wide range of mattresses and pillows specifically designed to reduce stress, induce deep sleep, and resolve spinal problems.


The company has deep Italian roots. Its innovative products are sourced, designed, and manufactured in the European country using the highest quality materials.  For over four decades, Mollyflex’s products have successfully combined beauty and comfort. Mollyflex has multiple product lines that are suitable for various settings and industries including homes, the hospitality sector, healthcare, etc.  


Mollyflex’s move to open a Dubai branch, yet again, emphasizes the importance of the UAE as an attractive destination for international brands. It also falls in line with Mollyflex’s plans to expand its market share by entering new territories.


Daniele Pennacchi and his sister Anna Pennacchi, Mollyflex co-founders, expressed their happiness at the opening of their first showroom in the UAE. This, they believe, will become a turning point in the company’s evolution and bring it closer to its customers in the region. The brand chose UAE as the perfect place for expansion due to their products’ appeal in the region.


On the occasion, Louay Aksh and Hussam Espir the General Managers of Royal Zone Furniture Company and Mollyflex partner brand in the UAE mentioned that “Mollyflex products will constitute an important addition to the local furniture market, particularly the more niched-down health-improving sleeping products segment of the market. The company is looking forward to maximizing the opportunities provided by the rapidly growing UAE market and has aggressive plans to open more branches in the future.”


This move becomes even more relevant in the wake of the policy changes introduced by the government recently. These changes are expected to attract more families and investors to the country and contribute to an increase in demand for furniture, especially for products designed by high-end international brands.


Founded in the city of Gedi, Brescia, in the Lombardy region of northern Italy, Mollyflex is owned and run by the Benacci family. The company maintains the well-known values of leading Italian brands and provides high-quality and aesthetically pleasing products. Its 10,000 sq. ft factory produces more than 1,000 mattresses a day and the Mollyflex team is continuously experimenting with new and latest technologies to make premium products. 


Apart from paying attention to the external appearance of its products, Mollyflex focuses on selecting the best raw materials to provide certified high-quality mattresses that best respond to the unique needs of each customer by ensuring comfortable and deeply restful sleep.


Mollyflex emphasis is on providing customers with the best value for money. Its products are accompanied by certificates that reflect its commitment to technical and health standards and signify the brand's reliability.






Micheline Macari

Landmark Global Review of the Engineering Response to Covid-19 Calls for Action to Ensure Future Pandemic Resilience


London, England-Thursday 29 September 2022

    Engineering X review of pandemic preparedness identifies key vulnerabilities

    Senior leaders endorse the need for comprehensive action by policymakers, business and academic leaders worldwide

Systemic barriers—including a lack of collaboration mechanisms, insufficient data and skills, and limited understanding and consideration of the role of engineering—reduced the ability of engineers to deliver timely and effective responses to the COVID-19 pandemic, according to a comprehensive review of the global engineering response, published today by Engineering X.

The findings of the global review will today be presented to senior delegates from 30 countries during the annual conference of the International Council of Academies of Engineering and Technological Sciences in Versailles, France.

The Global review of the engineering response to COVID-19: lessons learned for preparedness and resilience, produced in partnership with Dalberg Advisors, was conceived by the Engineering X Pandemic Preparedness programme at the height of the COVID-19 pandemic in November 2020 to learn lessons and make recommendations to ensure that a more systemic engineering response is put in place to improve preparedness for future pandemics.

Ensuring that datasets and data systems used for decision-making are up-to-date and bias-free, equipping emergency response task forces with more engineering capability, and encouraging the use of open science and data sharing standards are just three of the actions recommended by the review group.

Informed by data, case studies and comment from more than 40 countries, the review highlights the breadth of contributions made by engineers and engineering globally in responding to key challenges across sectors, disciplines, geographies, and across pandemic prevention, preparedness, response and recovery. It calls on governments, policy makers, public health actors, academia and funders, along with the engineering community, to identify and close structural gaps in resilience against future pandemics, to invest in skills, training and capacity of engineers all around the world, and to develop robust platforms for collaboration within engineering and between engineering and other disciplines.

The review highlights transformational innovations in low resource contexts as well as world-changing advances in medical and communication technologies, the pivotal role of data collection, distribution and management, and the importance of applying a systems lens to complex multifaceted challenges. It identifies six major challenges during COVID-19 where engineers made key contributions:

    Providing high-quality and timely data in near real-time and in appropriate formats, leveraging big data and mobile data for modelling and contact tracing.
    Innovating rapidly to provide novel health solutions, in collaboration with scientists and clinicians, such as in the design of PPE, diagnostics, breathing aids, vaccines and digital health tools.
    Designing products and services for diverse environments and user bases to reduce inequality of access and outcomes, such as customised PPE or wastewater testing and vaccine delivery for low-resource settings.
    Pivoting existing industrial capacity and building new capacity to ramp up production of essential medical and non-medical products such as alcohol manufacturers making hand sanitisers and expanding local vaccine manufacture.
    Upgrading and streamlining global supply chains to help delivery of essential medical and non-medical products, such as cold chains and drones for last mile delivery of vaccines.
    Bolstering and ensuring the resilience of societal systems and infrastructure, such as energy and water supplies, or expanding connectivity and digital solutions for remote education or working.

The report identifies key drivers that made engineers especially useful during the COVID-19 response, such as rallying around a shared sense of purpose, which empowered them to take risks and to innovate in unprecedented timeframes. For example, engineers from University College London (UCL) designed a breathing aid prototype in under 100 hours and partnered with Mercedes AMG, who repurposed their Formula 1 factories to produce 1,000 devices a day. The open-source design has been made available to local manufacturers around the world.

Professor Peter Guthrie OBE FREng, Chair of the Engineering X Pandemic Preparedness board that commissioned the review, said: “As the COVID-19 virus and its impact continues to evolve, there is a need to reflect on the efficacy of our response to it so far and how things might be handled better in the future. Our hope is that we can use the insights provided by this truly global overview of the engineering response to COVID-19 to better integrate engineering skills and habits of mind into resilience policies and structures all around the world, to improve our recovery from the virus, and to help us on the path to a safer, more prepared and resilient future.”

Professor Rebecca Shipley OBE, Director of the UCL Institute of Healthcare Engineering and Co-Lead of the UCL Ventura CPAP breathing device programme, said: “The COVID-19 pandemic has highlighted the pivotal role that engineers play in responding to public health emergencies and resilience planning. There are important lessons that we must learn around understanding the needs of providing healthcare in diverse, global settings and working collaboratively across sectors, listening and building trust. Now is the time for governments and international organisations to act on these lessons.”

Sir Richard Feachem KBE FREng, Professor Emeritus of Global Health at the Institute for Global Health Sciences, University of California San Francisco, said: “The COVID-19 pandemic has acted as a reminder that a global emergency requires a global response, and that no single country or discipline can tackle a crisis alone. This report reinforces this message and focuses on the role of engineering in this fight. It calls on the global community to learn lessons and act to improve our future pandemic response—creating better mechanisms for global collaboration and coordination, engaging with stakeholders from across disciplines, and developing the skills needed to prevent, prepare for and respond to pandemics.”


NB This press release and the Executive Summary of the global review are both available in French, Spanish and Arabic here:

  Notes for Editors

    Dalberg Advisors (2022). Global review of the engineering response to COVID-19: lessons learned for preparedness and resilience. Engineering X (founded by the Royal Academy of Engineering and Lloyd’s Register Foundation). ISBN: 978-1-909327-56-6
     CAETS, the International Council of Academies of Engineering and Technological Sciences, annual conference is being held in Versailles near Paris, France, 26–30 September 2022.
     Engineering X is an international collaboration, founded by the Royal Academy of Engineering and Lloyd’s Register Foundation, that brings together some of the world’s leading problem-solvers to address the great challenges of our age. Our global network of expert engineers, academics and business leaders is working to share best practice, explore new technologies, educate and train the next generation of engineers, build capacity, improve safety and deliver impact.
    The Engineering X Pandemic Preparedness Programme, led by the Royal Academy of Engineering, is supporting the UK and global engineering community to learn from the COVID-19 pandemic through global sharing of lessons on disruptive solutions and best practice approaches in the prevention, preparedness, response and recovery from pandemics.
    The Royal Academy of Engineering is harnessing the power of engineering to build a sustainable society and an inclusive economy that works for everyone. In collaboration with our Fellows and partners, we’re growing talent and developing skills for the future, driving innovation and building global partnerships, and influencing policy and engaging the public. Together we’re working to tackle the greatest challenges of our age.

The Academy, working with our partners in the National Engineering Policy Centre (NEPC), provided advice to government on a range of areas during the COVID-19 pandemic.

Royal Academy of Engineering

Pippa Cox

+44 20 7766 0745

Company Website

Mavenir Launches 5G Small Cell for High-Capacity In-building Standalone Coverage

 Ideal small cell for Communication Service Providers and Private Network Operators targeting 5G in-building coverage for enterprise and public spaces

(BUSINESS WIRE) -- Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the unveiling of its latest 5G small cell at the upcoming India Mobile Congress (IMC) event in Pragati Maidan, New Delhi.

Mavenir’s 5G small cell (E511), is a globally applicable product, with the flexibility to support both distributed and centralized ORAN architectures. Building on an established install base of over 2 million small cell units deployed globally, the 5G small cell forms part of an expanding small cell portfolio, that leverages Mavenir’s end-to-end RAN solution including a common Management System and CU. This flexibility, coupled with zero touch provisioning - ease of deployment, cost-effective, high-capacity solution is ideal for a variety of deployment use cases, including Enterprises such as office, retail, warehousing, manufacturing, and public spaces.

Puneet Sethi, Mavenir’s SVP and GM for the Radio Access Network Business, “By adding the 5G small cell to Mavenir’s product portfolio, we have competed our Multi-G (2G/3G/4G/5G), software upgradable, Open RAN-based small cells offering - enabling CSPs to enhance their network capacity and coverage for in-building use cases. The E511, is currently undergoing lab trials across India, Europe and US.”

A live product demonstration will be showcasing the 5G small cell in a Neutral Private Network configuration over Mavenir’s 5G SA Core at the India Mobile Congress, on the Mavenir Stand No. 4.4 – click here to request a meeting and demo.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.


View source version on



Maryvonne Tubb (US)

Emmanuela Spiteri (EMEA)